ATR

Over the past six months, AptarGroup's stock (ATR) experienced a 6.77% decline, with the price at $124.71 per share as of September 16, 2026, representing a 7.38% decline from the previous year. Key events included the Q1 2026 earnings release on May 5, 2026, which reported an 11% year-over-year sales increase but an 8% decline in adjusted EPS and reduced net income. The Annual General Meeting on May 6, 2026, saw stockholders approve executive compensation and ratify the independent accounting firm. The Q2 2026 earnings release on July 30, 2026, reported $1.42 EPS and $1.03 billion in revenue, both exceeding analyst estimates. Gael Touya was set to become CEO on September 1, 2026, and Aptar Pharma announced a collaboration with Massachusetts General Hospital on September 14, 2026, to advance nose-to-brain drug delivery. Additionally, AptarGroup declared quarterly dividends, with the last dividend per share being $0.48.